IBDEI07P ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3442,1,5,0)
 ;;=5^Xerotic Eczema
 ;;^UTILITY(U,$J,358.3,3442,2)
 ;;=^27800
 ;;^UTILITY(U,$J,358.3,3443,0)
 ;;=686.8^^31^282^6
 ;;^UTILITY(U,$J,358.3,3443,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3443,1,2,0)
 ;;=2^686.8
 ;;^UTILITY(U,$J,358.3,3443,1,5,0)
 ;;=5^Pustular Eczema
 ;;^UTILITY(U,$J,358.3,3443,2)
 ;;=^88097
 ;;^UTILITY(U,$J,358.3,3444,0)
 ;;=690.18^^31^282^7
 ;;^UTILITY(U,$J,358.3,3444,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3444,1,2,0)
 ;;=2^690.18
 ;;^UTILITY(U,$J,358.3,3444,1,5,0)
 ;;=5^Seborrheic Eczema
 ;;^UTILITY(U,$J,358.3,3444,2)
 ;;=^303310
 ;;^UTILITY(U,$J,358.3,3445,0)
 ;;=705.81^^31^282^3
 ;;^UTILITY(U,$J,358.3,3445,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3445,1,2,0)
 ;;=2^705.81
 ;;^UTILITY(U,$J,358.3,3445,1,5,0)
 ;;=5^Dyshidrotic Eczema/Pompholyx
 ;;^UTILITY(U,$J,358.3,3445,2)
 ;;=Dyshidrotic Eczema/Pompholyx^96545
 ;;^UTILITY(U,$J,358.3,3446,0)
 ;;=692.9^^31^282^2
 ;;^UTILITY(U,$J,358.3,3446,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3446,1,2,0)
 ;;=2^692.9
 ;;^UTILITY(U,$J,358.3,3446,1,5,0)
 ;;=5^Atopic Eczema
 ;;^UTILITY(U,$J,358.3,3446,2)
 ;;=^27800
 ;;^UTILITY(U,$J,358.3,3447,0)
 ;;=274.89^^31^282^4
 ;;^UTILITY(U,$J,358.3,3447,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3447,1,2,0)
 ;;=2^274.89
 ;;^UTILITY(U,$J,358.3,3447,1,5,0)
 ;;=5^Gouty Eczema
 ;;^UTILITY(U,$J,358.3,3447,2)
 ;;=^267936
 ;;^UTILITY(U,$J,358.3,3448,0)
 ;;=782.3^^31^283^3
 ;;^UTILITY(U,$J,358.3,3448,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3448,1,2,0)
 ;;=2^782.3
 ;;^UTILITY(U,$J,358.3,3448,1,5,0)
 ;;=5^Pitting Edema
 ;;^UTILITY(U,$J,358.3,3448,2)
 ;;=^38340
 ;;^UTILITY(U,$J,358.3,3449,0)
 ;;=459.2^^31^283^2
 ;;^UTILITY(U,$J,358.3,3449,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3449,1,2,0)
 ;;=2^459.2
 ;;^UTILITY(U,$J,358.3,3449,1,5,0)
 ;;=5^Edema d/t Venous Obstruction
 ;;^UTILITY(U,$J,358.3,3449,2)
 ;;=^269850
 ;;^UTILITY(U,$J,358.3,3450,0)
 ;;=457.1^^31^283^1
 ;;^UTILITY(U,$J,358.3,3450,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3450,1,2,0)
 ;;=2^457.1
 ;;^UTILITY(U,$J,358.3,3450,1,5,0)
 ;;=5^Edema d/t Lymphatic Obstruction
 ;;^UTILITY(U,$J,358.3,3450,2)
 ;;=^87693
 ;;^UTILITY(U,$J,358.3,3451,0)
 ;;=695.2^^31^284^2
 ;;^UTILITY(U,$J,358.3,3451,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3451,1,2,0)
 ;;=2^695.2
 ;;^UTILITY(U,$J,358.3,3451,1,5,0)
 ;;=5^Erythema Nodosum
 ;;^UTILITY(U,$J,358.3,3451,2)
 ;;=^42065
 ;;^UTILITY(U,$J,358.3,3452,0)
 ;;=692.71^^31^284^3
 ;;^UTILITY(U,$J,358.3,3452,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3452,1,2,0)
 ;;=2^692.71
 ;;^UTILITY(U,$J,358.3,3452,1,5,0)
 ;;=5^Erythema Solara
 ;;^UTILITY(U,$J,358.3,3452,2)
 ;;=^115798
 ;;^UTILITY(U,$J,358.3,3453,0)
 ;;=695.0^^31^284^4
 ;;^UTILITY(U,$J,358.3,3453,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3453,1,2,0)
 ;;=2^695.0
 ;;^UTILITY(U,$J,358.3,3453,1,5,0)
 ;;=5^Erythema Toxic
 ;;^UTILITY(U,$J,358.3,3453,2)
 ;;=^265514
 ;;^UTILITY(U,$J,358.3,3454,0)
 ;;=695.10^^31^284^1
 ;;^UTILITY(U,$J,358.3,3454,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3454,1,2,0)
 ;;=2^695.10
 ;;^UTILITY(U,$J,358.3,3454,1,5,0)
 ;;=5^Erythema Multiforme NOS
 ;;^UTILITY(U,$J,358.3,3454,2)
 ;;=^336759
 ;;^UTILITY(U,$J,358.3,3455,0)
 ;;=V15.89^^31^285^6
 ;;^UTILITY(U,$J,358.3,3455,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3455,1,2,0)
 ;;=2^V15.89
 ;;^UTILITY(U,$J,358.3,3455,1,5,0)
 ;;=5^Persian Gulf Service
 ;;^UTILITY(U,$J,358.3,3455,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,3456,0)
 ;;=V15.84^^31^285^1
 ;;^UTILITY(U,$J,358.3,3456,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3456,1,2,0)
 ;;=2^V15.84
 ;;^UTILITY(U,$J,358.3,3456,1,5,0)
 ;;=5^Exposure To Asbestos
